ArticleScientific reports2017
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Integrative metabolomics reveals unique metabolic traits in Guillain-Barré Syndrome and its variants.Scientific reports · 2019Trial
- A Comprehensive Description of the Roadmap to Identify and Validate a Myelin Biomarker.Biomarker insights · 2025Article
- CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Monitoring Myelin Lipid Composition and the Structure of Myelinated Fibers Reveals a Maturation Delay in CMT1A.International journal of molecular sciences · 2024Article
- Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.Neurology research international · 2024Article
- [Prognostic and monitoring biomarkers in chronic inflammatory demyelinating polyneuropathy].Revista de neurologia · 2022Review
- Plasma Metabolomics and Lipidomics Differentiate Obese Individuals by Peripheral Neuropathy Status.The Journal of clinical endocrinology and metabolism · 2022Observational
- Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review.Diagnostics (Basel, Switzerland) · 2021Review
- CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS.Journal of neurology, neurosurgery, and psychiatry · 2021Article
- Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-Barré syndrome.Scientific reports · 2020Article
- Statistically Driven Metabolite and Lipid Profiling of Patients from the Undiagnosed Diseases Network.Analytical chemistry · 2020Article
- Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A.Frontiers in neurology · 2020Article
- Time Course of Metabolomic Alterations in Cerebrospinal Fluid After Aneurysmal Subarachnoid Hemorrhage.Frontiers in neurology · 2020Article
- Article
- Advances in ex vivo models and lab-on-a-chip devices for neural tissue engineering.Biomaterials · 2019Review
- Peripheral Demyelinating Diseases: From Biology to Translational Medicine.Frontiers in neurology · 2019Review
- Plasma Lipid Profiling Identifies Biomarkers of Cerebral Microvascular Disease.Frontiers in neurology · 2019Article
- White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.Brain : a journal of neurology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fast, accurate and reliable methods to quantify the amount of myelin still lack, both in humans and experimental models. The overall objective of the present study was to demonstrate that sphingomyelin (SM) in the cerebrospinal fluid (CSF) of patients affected by demyelinating neuropathies is a myelin biomarker. We found that SM levels mirror both peripheral myelination during development and small myelin rearrangements in experimental models. As in acquired demyelinating peripheral neuropathies myelin breakdown occurs, SM amount in the CSF of these patients might detect the myelin loss. Indeed, quantification of SM in 262 neurological patients showed a significant increase in patients with peripheral demyelination (p = 3.81 * 10 - 8) compared to subjects affected by non-demyelinating disorders. Interestingly, SM alone was able to distinguish demyelinating from axonal neuropathies and differs from the principal CSF indexes, confirming the novelty of this potential CSF index. In conclusion, SM is a specific and sensitive biomarker to monitor myelin pathology in the CSF of peripheral neuropathies. Most importantly, SM assay is simple, fast, inexpensive, and promising to be used in clinical practice and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.